Early cancer detection startup Craif raises $22M

Cancer is one of the leading causes of global death. National Cancer Institute About 20 million new cancer cases and 1.7 million cancer deaths were reported worldwide in 2022, the estimates increased by 20.5 million new cases by 2021.

CreafSeparate from Nagoa University in 2018, using MicroRNA (MIRNA) to develop an AI -driven primary cancer detection software, and it has collected $ 22 million for Series C Fund to further expand and extend its research and development.

CRIF co-founder and chief executive officer Ruchi Onoz told TechCrunch an interview that the company had completed its series C funding round below just $ 1 million.

X and KSKAn existing investor has led the latest funds, which brings the US-based investor non-irrational groups, Japanese startups, Towns Laboratories, Diava House Industry and Aojora Bank Group to its total $ 57 million.

The crime’s journey began when Osose saw how deeply his family influenced his family, both grandparents were infected with the disease. These personal experiences have inspired Strong’s promise to help solve cancer problems. Assistant Professor Ooz and money of Nagoa University and Yasui are also co-founded by Crif a month after they met. Yasui created a new method for detection of initial cancer using the urinary tract biomearker.

Osoose said the initial identification of treatmentable conditions could be challenging because traditional diagnostic diagnostic methods like blood tests can be aggressive, causing some people to avoid regular screening, Onsoz said. Also, limited access to the treatment facilities in certain cases makes it challenging for people to easily test cancer, according to Onoj.

The CRIF’s goal was to solve these gaps by providing a non-aggressive urine-based test that enables primary cancer detection, even in very early stages, such as stage 1.

“The test may be conducted from a patient’s home comfort and made by an advanced microRNA analysis, making the initial identification more accessible and effective,” said onos. “Our users are health -conscious people who are concerned about cancer but it seems challenging to the conventional screening because of the limitations of time, expense and accessibility.”

Several startups are creating platforms for initial cancer detection in the industry, as Graph, Frinome, Delphi Diagnostics And Clearnote HealthThe

Instead of CFDNA (Cell-Free DNA), the CRIF separates itself by using the microRNA as a biomeork, like most competitors.

“Mirna, which gained more intense recognition after being connected 2024 Nobel PrizeEven in the biology of cancer, even in the early stages of deep involvement, “Onoj explained.

Another unique aspect of its product is its use of urine. Onoj said that the urine provides simple and non-aggressive, many scientific and practical benefits. He also added that the biometer’s signals make it clear, it has less impurities than other samples. It helps reduce the errors of any measure like hemolysis in the blood and save money in the test.

The first product of the crip, a test, a test that detects the risk of seven separate cancer (pancreatic, colorectal, lung, stomach, esophagus breast, ovary) is already creating earnings in Japan using urinary tract MRNA. CEO of the company said that the products are distributed through clinics, pharmacy, direct-to-customer sales and corporate well-being programs, which provide different types of revenue sources that can be expanded.

“We are partners in Japan with more than 1000 medical institutions and about 600 pharmacies, serving about 20,000 users. Our team consists of 731 dedicated employees,” tells Techchen.

The revenue model provides both single tests and subscription packages for regular examination, many users choose for subscription plans. It has earned millions of dollars in 2021 and aims to produce $ 15 million later this year, Onoz told TechCrunch.

Craig has intended to enhance the opportunity to incorporate more than ten different types of cancer in the coming years. Furthermore, the startup is ready to use its technology for neurodizerrative disorders such as dementia for initial detection of non-cancer diseases.

Crif has a R&D lab in California’s Irvine and plans to open another office to conduct his business activities in San Diego.

The new fund will help the startup to enter the US market through its missing, to complete trials in the United States at the end of 2026 and to get the FDA approval in early 2027.

It has already started collecting pancreatic cancer samples in collaboration with 30 medical institutions across the United States of the United States.